N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Phase 1 / Phase 2 ClinicalTrials.gov

DIAG723 in Adults With Hereditary Hemorrhagic Telangiectasia

Sponsor: Diagonal Therapeutics, Inc. • ClinicalTrials.gov ID: NCT07623525

Registry updated: 2026-09-08
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

This is a Phase 1/2, randomized, double-blind, placebo-controlled, first-in-human study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of subcutaneously administered DIAG723 in adult patients with hereditary hemorrhagic telangiectasia (HHT). The study consists of three parts: Part A (dose escalation): Single ascending subcutaneous doses of DIAG723 are evaluated in sequential cohorts to assess safety, tolerability, and pharmacokinetics. Part B (dose expansion): Multiple doses of DIAG723 administered over 13 weeks are evaluated in patients with HHT to assess safety and preliminary efficacy. Part C (dose expansion): Multiple doses of DIAG723 administered over 13 weeks are evaluated in patients with HHT and concomitant pulmonary arterial hypertension to assess safety and exploratory clinical effects in this population. Participants will be randomized within each study part to receive DIAG723 or placebo. The study includes dose escalation in Part A and dose expansion in Parts B and C.

Interventions

  • DIAG723 (Biological)
    Bispecific agonist monoclonal antibody targeting ALK-1 and BMPRII, administered subcutaneously as: Single ascending dose in Part A; Multiple doses (7 doses over 13 weeks) in Parts B and C
  • Placebo (Other)
    Sterile normal saline (0.9% NaCl) administered subcutaneously in volumes matched to DIAG723 to maintain study blinding.

Eligibility criteria

Inclusion Criteria: * Adult patients ≥18 years with a clinical or genetic diagnosis of HHT * Adequate hepatic and renal function * Part B: Epistaxis and anemia or transfusion/iron history * Part C: HHT with documented pre-capillary pulmonary arterial hypertension Exclusion Criteria: * Active or recent systemic infection * Recent thromboembolic events * Use of anti-angiogenic drugs within 6 weeks * Pregnancy or lactation * Recent participation in another investigational study

Conditions

Hereditary Hemorrhagic Telangiectasia Pulmonary Arterial Hypertension

Locations

  • Diagonal Investigational Site — Camperdown, New South Wales, Australia
  • Diagonal Investigational Site — Randwick, New South Wales, Australia
  • Diagonal Investigational Site — Herston, Queensland, Australia
  • Diagonal Investigational Site — Herston, Queensland, Australia
  • Diagonal Investigational Site — East Melbourne, Victoria, Australia
  • Diagonal Investigational Site — Parkville, Victoria, Australia
  • Diagonal Investigational Site — West Perth, Western Australia, Australia
  • Diagonal Investigational Site — Toronto, Ontario, Canada
  • Diagonal Investigational Site — Toronto, Ontario, Canada
  • Diagonal Investigational Site — Laval, Quebec, Canada
  • Diagonal Investigational Site — Grafton, Auckland, New Zealand
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record